N E W ! S V A ! MAKE 15-90 TIMES YOUR MONEY - S V A - 500 Beiträge pro Seite
eröffnet am 11.09.05 00:48:08 von
neuester Beitrag 11.09.05 21:19:09 von
neuester Beitrag 11.09.05 21:19:09 von
Beiträge: 78
ID: 1.006.073
ID: 1.006.073
Aufrufe heute: 0
Gesamt: 1.505
Gesamt: 1.505
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| gestern 19:46 | 6955 | |
| gestern 21:56 | 5647 | |
| vor 1 Stunde | 4931 | |
| gestern 21:21 | 4540 | |
| vor 1 Stunde | 3184 | |
| gestern 19:32 | 2325 | |
| gestern 14:53 | 1982 | |
| vor 36 Minuten | 1832 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.182,00 | +0,59 | 217 | |||
| 2. | 3. | 0,1885 | -0,26 | 90 | |||
| 3. | 2. | 1,1800 | -14,49 | 77 | |||
| 4. | 5. | 9,3575 | +0,27 | 60 | |||
| 5. | 4. | 169,14 | -0,61 | 50 | |||
| 6. | Neu! | 0,4400 | +3,53 | 36 | |||
| 7. | Neu! | 4,8025 | +6,45 | 34 | |||
| 8. | Neu! | 11,828 | +13,73 | 31 |
Feedback
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. ("Sinovac") ("the Company") (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Trading Spotlight
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. ("Sinovac") ("the Company") (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, "this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. "bird flu"). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. ("Sinovac") ("the Company") (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, "this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. "bird flu"). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE "SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
ANGANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/2ulu2
http://tinyurl.com/2ulu2
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
ANFANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/2ulu2
http://tinyurl.com/2ulu2
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
Sinovac Biotech Ltd. Receives Flu Vaccine Production License from Chinese FDA
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Author：SINOVAC BIOTECH CO., LTD. Issue Time：2005-7-28 11:06:32 Hits：134
BEIJING--(BUSINESS WIRE)--July 27, 2005--Sinovac Biotech Ltd. (" Sinovac" ) (" the Company" ) (AMEX:SVA - News) announced today that the State Food and Drug Administration (SFDA) issued a production license for Sinovac`s proprietary influenza flu vaccine, Anflu(TM).
The SFDA issued a new drug certificate for Anflu(TM) in March 2005, which provided Sinovac proprietary privileges for the vaccine. The production license was received July 27th (Beijing time), and authorizes Sinovac to begin vaccine production.
Sinovac has already installed and tested all the latest production equipment into the facility and is ready to complete the final step in the application process for Good Manufacturing Practices (GMP) certification. Once approved, Sinovac will have three GMP certified state-of-the-art vaccine products selling in China. Sinovac`s other two products include Healive(TM), which immunizes against hepatitis A, and Bilive(TM), which immunizes against hepatitis A and hepatitis B.
The Company`s new flu production line is situated at a new manufacturing facility next to its existing Beijing headquarters. The 2,600 square-meter facility has a production capacity of 2 million flu vaccine doses per year. This production line can also be used to produce a pandemic influenza (avian flu) vaccine for humans against the H5N1 virus.
Sinovac President and CEO, Mr. Weidong Yin remarked, " this important development demonstrates Sinovac`s continued strengths and progress in all fundamental areas. We made a complimentary corporate development plan for developing and commercializing vaccines to combat conventional and emerging viruses. Receiving our third production license is one of the important developments for the company`s conventional-side of our plan. Now we are gaining momentum with each success. I am truly excited to show the world all of our tremendous vaccine and business achievements."
Markets
Sinovac developed the Anflu(TM) vaccine in response to the fast growing influenza vaccine market in China. It is estimated that yearly influenza vaccine shortfalls will be as much as 15 to 20 million doses. Split type vaccines are the most widely used influenza vaccines due to their higher safety record. Anflu(TM) is a split vaccine and Sinovac intends to establish itself as the market leader for split influenza vaccine production.
With an aging population and a growing health-conscious middle class, the demand for safe and efficacious influenza vaccines is growing by as much as 16% (compounded annual growth rate) per year in China.
Ideally, Anflu(TM) marketing will begin in late summer of 2005, with sales expected to begin in the last quarter of 2005. After it is approved for sales to the public, Sinovac will utilize the same sales and distribution channels as they do for Healive(TM) and Bilive(TM). With the advent of a third major product Sinovac is leveraging their growing name recognition and stellar reputation in the domestic market. The timing of Anflu sales depends on the date the SFDA approves the production line.
Regulations
In order to comply with China`s drug administration regulations, a new vaccine must have both a new drug certificate and a production license before it can apply for GMP certification. Once all three of these requirements are met, the company can mass produce vaccines and sell them.
The New Drug Certificate grants the filing Company intellectual property rights to the drug. In accordance with World Trade Organization (WTO) agreements, Sinovac`s latest vaccine now receives global proprietary protection.
About the SFDA
China`s State Food and Drug Administration (SFDA), is the highest state authority governing the nation`s drug industry. The SFDA`s main functions include the approval of drug registrations, the drafting and enforcement of industrial standards, and the issuing of licenses. The role and standing of the SFDA are essentially those of the FDA (Food & Drug Administration) in the United States. Without exception, all local and foreign drugs produced and/or marketed in China are required to meet relevant SFDA standards as a pre-requisite to their regular use and they are strictly bound by SFDA regulations.
About Sinovac Biotech Ltd.
Sinovac Biotech Ltd. is committed to becoming a world leader in the research and development, manufacture and commercialization of vaccines for endemic and pandemic viruses such as hepatitis and influenza, and for fast emerging viruses such as SARS and Avian Flu Influenza (a.k.a. " bird flu" ). The Company`s objective is to provide Chinese children with the best vaccines in the world, and let children in the world use vaccines made in China.
Additional information is available on the Company website, http://www.sinovac.com/en/index.asp
To receive press releases, additional information, investor newsletters and corporate updates, please email your request to: info@sinovac.com
THIS NEWS RELEASE MAY INCLUDE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED, WITH RESPECT TO ACHIEVING CORPORATE OBJECTIVES, DEVELOPING ADDITIONAL PROJECT INTERESTS, SINOVAC`S ANALYSIS OF OPPORTUNITIES IN THE ACQUISITION AND DEVELOPMENT OF VARIOUS PROJECT INTERESTS AND CERTAIN OTHER MATTERS. THESE STATEMENTS ARE MADE UNDER THE " SAFE HARBOR" PROVISIONS OF THE UNITED STATES PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 AND INVOLVE RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.
Chart-Analyst: Bullish Signals
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
MACD generates bullish signals:
1. Positive divergence
2. Bullish moving average crossover
3. Bullish centerline crossover
http://tinyurl.com/aacqc Hinweis: Ende 2003 Ausbruch SARS!
Gallery View:
http://tinyurl.com/dfbyu" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/dfbyu
http://tinyurl.com/dfbyu" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/dfbyu
ANFANG 2003 AUSBRUCH SARS - WIEDERHOLT SICH DAS SZENARIO MIT DER VOGELGRIPPE?
http://tinyurl.com/2ulu2
http://tinyurl.com/2ulu2
...aber Notebook...du bist nicht zufällig schon befallen??? 
[posting]17.855.352 von notebook am 11.09.05 01:36:28[/posting]ich habe angst vor dir 
[posting]17.855.352 von notebook am 11.09.05 01:36:28[/posting]Heiiijjj !
Kauf Dir ein neues Notebook. Mit dem jetzigen stimmt was nicht !
Blanca
Kauf Dir ein neues Notebook. Mit dem jetzigen stimmt was nicht !
Blanca http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
#36 Bist du hellseher? 
Ich bin kein Hellseher - aber um es in der Sprache der Experten auszudrücken, die Wahrscheinlichkeit ist gross. Liess selber:
DIE VOGELGRIPPE KOMMT!
http://tinyurl.com/aupjz
http://tinyurl.com/7rlgv
http://tinyurl.com/8ek6m
http://tinyurl.com/a582d
http://tinyurl.com/c2w2m
http://tinyurl.com/afp73" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/afp73
http://tinyurl.com/9ck8l" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/9ck8l
http://tinyurl.com/d4kgh" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/d4kgh
DAS THEMA WIRD IN DEN MEDIEN NOCH ZURÜCKGEHALTEN, WEIL DIE POLITIKER ANGST VOR EINER MASSENPANIK HABEN. WAS GLAUBST DU PASSIERT, WENN SCHON NUR ERSTE GERÜCHTE IM UMFLAUF SIND, DAS VIRUS KÖNNTE SICH MIT DEM GRIPPEVIRUS VERMISCHT HABEN. OBIGE LINKS ENTHALTEN AUCH DIE MEINUNG DER WHO (Weltgesundheitsorganisation)!
DIE VOGELGRIPPE KOMMT!
http://tinyurl.com/aupjz
http://tinyurl.com/7rlgv
http://tinyurl.com/8ek6m
http://tinyurl.com/a582d
http://tinyurl.com/c2w2m
http://tinyurl.com/afp73" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/afp73
http://tinyurl.com/9ck8l" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/9ck8l
http://tinyurl.com/d4kgh" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/d4kgh
DAS THEMA WIRD IN DEN MEDIEN NOCH ZURÜCKGEHALTEN, WEIL DIE POLITIKER ANGST VOR EINER MASSENPANIK HABEN. WAS GLAUBST DU PASSIERT, WENN SCHON NUR ERSTE GERÜCHTE IM UMFLAUF SIND, DAS VIRUS KÖNNTE SICH MIT DEM GRIPPEVIRUS VERMISCHT HABEN. OBIGE LINKS ENTHALTEN AUCH DIE MEINUNG DER WHO (Weltgesundheitsorganisation)!
Ausbruch Vogelgrippe Monat August!
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
Hinweis: Ich versuch hier die Aktie ein wenig bekannter zu machen. Das ist offensichtlich. Aber ich habe zu jeder Aussage die entsprechenden Quellen (Links) angegeben. Und abgesehen vom Pusherblättchen, dass eine sehr optimistische Sichtweise wiederspiegelt, sind alle anderen Quellen sehr zuverlässig.
Die Vogelgrippe kommt - das ist keine Frage. Die Frage ist höchstens wann. Die Situation war aber noch nie so beunruhigend wie in diesem Jahr.
Die Vogelgrippe kommt - das ist keine Frage. Die Frage ist höchstens wann. Die Situation war aber noch nie so beunruhigend wie in diesem Jahr.
Mit Sinovac investiert man in ein Unternehmen, dass im Wachstumsmarkt China hervorragend positioniert ist und von der Regierung unterstützt wird. Sinovac hat eine breite Produktepipeline.
Auch ohne Vogelgrippe hat die Aktie blendende Zukunftsaussichten.
Auch ohne Vogelgrippe hat die Aktie blendende Zukunftsaussichten.
"Wir erwarten eine verheerende Influenza-Pandemie innerhalb der kommenden Monate in Deutschland", verkündete kürzlich Adel Massaad, Leiter des deutschen Instituts für Gesundheitsaufklärung (IFGA).
Quelle: http://tinyurl.com/d4kgh
Quelle: http://tinyurl.com/d4kgh
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
DIE VOGELGRIPPE KOMMT!
http://tinyurl.com/aupjz" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/aupjz
http://tinyurl.com/aupjz" target="_blank" rel="nofollow ugc noopener">
http://tinyurl.com/aupjz
- DAS VOGELGRIPPE-VIRUS EXISTIERT NOCH NICHT IN DER FORM, DASS ES SICH RASCH VON MENSCH ZU MENSCH AUSBREITET - EXPERTEN GEHEN ABER DAVON AUS, DASS SICH DAS VIRUS MIT DEM GRIPPEVIRUS VERBINDET - SINOVAC WAR DIE ERSTE FIRMA, WELCHE EINEN IMPFSTOFF GEGEN SARS ENTWICKELTE - SINOVAC WIRD AUCH DIE ERSTE FIRMA SEIN, WELCHE EINEN IMPFSTOFF GEGEN DAS MUTIERTE VOGELGRIPPEVIRUS AUF DEN MARKT BRINGT !
http://tinyurl.com/dr67h
http://tinyurl.com/dr67h
" Wir erwarten eine verheerende Influenza-Pandemie innerhalb der kommenden Monate in Deutschland" , verkündete kürzlich Adel Massaad, Leiter des deutschen Instituts für Gesundheitsaufklärung (IFGA).
Quelle: http://tinyurl.com/d4kgh
Quelle: http://tinyurl.com/d4kgh
Ausbruch Vogelgrippe Monat Juli
Siehe Karte unter folgendem Link:
http://tinyurl.com/bab5y
Ausbruch Vogelgrippe Monat August!
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
Siehe Karte unter folgendem Link:
http://tinyurl.com/bab5y
Ausbruch Vogelgrippe Monat August!
Siehe Karte unter nachfolgendem Link:
http://tinyurl.com/8z552
Hinweis: Die Forscher sind sehr besorgt darüber, dass sich das Virus sogar in den Sommermonaten so schnell verbreitet. Und in Vietnam sind sogar bereits Fälle aufgetreten, wo eine Mensch zu Mensch - Übertragung nicht auszuschliessen ist.
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
@Fragenhaber
Du solltest besser Angst vor der Vogelgrippe haben!
" Wir erwarten eine verheerende Influenza-Pandemie innerhalb der kommenden Monate in Deutschland" , verkündete kürzlich Adel Massaad, Leiter des deutschen Instituts für Gesundheitsaufklärung (IFGA).
Quelle: http://tinyurl.com/d4kgh
Hoffen wir, dass die Politiker vernüftig genug sind, die entsprechenden Vorsichtsmassnahmen einzuleiten.
Was Sinovac betrifft - es reicht, wenn die Medien anfangen stärker über die Vogelgrippe zu berichten. Für einen Hype reichen schon Gerüchte.
Hinweis: Von Oktober bis März ist Grippezeit. Das Kerngeschäft von Sinovac sind Impfungen!
Du solltest besser Angst vor der Vogelgrippe haben!
" Wir erwarten eine verheerende Influenza-Pandemie innerhalb der kommenden Monate in Deutschland" , verkündete kürzlich Adel Massaad, Leiter des deutschen Instituts für Gesundheitsaufklärung (IFGA).
Quelle: http://tinyurl.com/d4kgh
Hoffen wir, dass die Politiker vernüftig genug sind, die entsprechenden Vorsichtsmassnahmen einzuleiten.
Was Sinovac betrifft - es reicht, wenn die Medien anfangen stärker über die Vogelgrippe zu berichten. Für einen Hype reichen schon Gerüchte.
Hinweis: Von Oktober bis März ist Grippezeit. Das Kerngeschäft von Sinovac sind Impfungen!
[posting]17.856.426 von notebook am 11.09.05 11:55:19[/posting]Druckansicht | PDF-Download | Nachricht versenden
Impfstoff gegen Vogelgrippe im Test erfolgreich
10.08.2005 - (dpa) Ein Impfstoff gegen Vogelgrippe ist in Tests an Menschen erfolgreich gewesen. «Wir haben einen Impfstoff», sagte Anthony S. Fauci der Tageszeitung «New York Times». Er ist Direktor des Nationalen Instituts für Allergien und Infektionskrankheiten der USA.Anzeige
Der Impfstoff soll vor dem Vogelgrippe-Virus H5N1 schützen, das zur Zeit in Asien grassiert. Gesunde Versuchspersonen hatten nach der Impfung Abwehrstoffe gegen das Virus gebildet. Allerdings seien weitere Tests nötig, und es werde noch einige Monate dauern, bis der Impfstoff tatsächlich für die Öffentlichkeit zur Verfügung stehe, schränkte Fauci ein.
Ein Impfstoff könnte helfen, eine weltweite Ausbreitung des Grippevirus zu verhindern. Nach Angaben der Weltgesundheitsorganisation (WHO) erkrankten seit Ende 2003 117 Menschen, von denen 57 starben. Eine Übertragung von Mensch zu Mensch ist nur in äußerst seltenen Fällen aufgetreten. Ein einfacher Übertragungsweg ist jedoch Voraussetzung für eine rasante weltweite Ausbreitung der gefürchteten Grippe. Ein entsprechend gefährliches Virus kennen die Forscher noch nicht und können daher auch keinen maßgeschneiderten Impfstoff dagegen entwickeln.
Nach Angaben von Fauci haben die USA Impfstoffmengen bestellt, die für 450.000 Menschen reichen würden. Erste Berichte zu dem nun getesteten Impfstoff gab es bereits im vergangenen September.
Impfstoff gegen Vogelgrippe im Test erfolgreich
10.08.2005 - (dpa) Ein Impfstoff gegen Vogelgrippe ist in Tests an Menschen erfolgreich gewesen. «Wir haben einen Impfstoff», sagte Anthony S. Fauci der Tageszeitung «New York Times». Er ist Direktor des Nationalen Instituts für Allergien und Infektionskrankheiten der USA.Anzeige
Der Impfstoff soll vor dem Vogelgrippe-Virus H5N1 schützen, das zur Zeit in Asien grassiert. Gesunde Versuchspersonen hatten nach der Impfung Abwehrstoffe gegen das Virus gebildet. Allerdings seien weitere Tests nötig, und es werde noch einige Monate dauern, bis der Impfstoff tatsächlich für die Öffentlichkeit zur Verfügung stehe, schränkte Fauci ein.
Ein Impfstoff könnte helfen, eine weltweite Ausbreitung des Grippevirus zu verhindern. Nach Angaben der Weltgesundheitsorganisation (WHO) erkrankten seit Ende 2003 117 Menschen, von denen 57 starben. Eine Übertragung von Mensch zu Mensch ist nur in äußerst seltenen Fällen aufgetreten. Ein einfacher Übertragungsweg ist jedoch Voraussetzung für eine rasante weltweite Ausbreitung der gefürchteten Grippe. Ein entsprechend gefährliches Virus kennen die Forscher noch nicht und können daher auch keinen maßgeschneiderten Impfstoff dagegen entwickeln.
Nach Angaben von Fauci haben die USA Impfstoffmengen bestellt, die für 450.000 Menschen reichen würden. Erste Berichte zu dem nun getesteten Impfstoff gab es bereits im vergangenen September.
@Blanca_die_Haesin
Interessanter Artikel, den ich bereits kenne. Als ich anfing, mich mit der Aktie zu befassen, machte ich zu Beginn die gleiche Überlegung.
Folgendes:
1. Es kann noch gar keinen Impfstoff geben, weil es auch das Virus in der Endform noch nicht gibt.
2. H5N1 verändert sich ständig und wird resistenter.
3. Was die WHO (Weltgesundheitsorganisation) beunruhigt, ist, dass sich das Vogelgrippevirus mit dem menschlichen Grippevirus verbindet. Dafür gibt es noch keinen Impfstoff - weil es wie gesagt das Virus noch nicht gibt.
4. Sinovac hat bei SARS entgegen allen Erwartungen als erste Unternehmung ein Mittel auf den Markt gebracht. Dies war möglich, weil in China die Zulassungen sehr schnell erteilt werden , wenn es darauf ankommt. - Die haben damals das Virus direkt am Menschen getestet und gewisse Schritte einfach übersprungen.
5. Natürlich wird es einen Konkurrenzkampf geben. Es ist anzunehmen, dass eine Firma alleine nicht in der Lage sein wird, die Welt mit Impfstoffen zu versorgen.
6. Man könnte auch Roche-Aktien kaufen. Zurzeit ist Tamiflu vielversprechend. Allerdings ist Tamiflu für Roche nur ein Nebengleis. Ist ja ne riesige Firma. Es ist daher nicht anzunehmen, dass eine Vogelgrippe bei Roche einen Vervielfacher auslösen wird.
7. China ist ein riesiger Markt.
8. Auch im obigen Artikel wird darauf hingewiesen, dass noch weitere Tests nötig sind.
9. Die meisten Menschen wissen noch nicht einmal, dass es eine Pandemie geben könnte. Aber die Biotechs wissen das schon lange. Wenn die Vogelgrippe ausbrechen wird, gibt es einen Hype bei Biotechs, welche Impfstoffe gegen die Vogelgrippe entwickeln. Sobald ein Impfstoff da ist, werden vermutlich alle sagen - jetzt kaufen. Gerade dann ist aber der Zeitpunkt um auszusteigen. - War bei SARS auch so. Aktie ist von 0.2 auf 6 Dollar gestiegen. Im März 2004 haben dann alle " kaufen" geschrien. Dann gings aber wieder runter mit dem Kurs.
Buy on bad news, sell on good news. Das ist ja der Witz der Sache. Wenn sich alle der Gefahr einer Pandemie bewusst wären, könnte man Sinovac nicht zum Kurs von 3.5$ kaufen.
Interessanter Artikel, den ich bereits kenne. Als ich anfing, mich mit der Aktie zu befassen, machte ich zu Beginn die gleiche Überlegung.
Folgendes:
1. Es kann noch gar keinen Impfstoff geben, weil es auch das Virus in der Endform noch nicht gibt.
2. H5N1 verändert sich ständig und wird resistenter.
3. Was die WHO (Weltgesundheitsorganisation) beunruhigt, ist, dass sich das Vogelgrippevirus mit dem menschlichen Grippevirus verbindet. Dafür gibt es noch keinen Impfstoff - weil es wie gesagt das Virus noch nicht gibt.
4. Sinovac hat bei SARS entgegen allen Erwartungen als erste Unternehmung ein Mittel auf den Markt gebracht. Dies war möglich, weil in China die Zulassungen sehr schnell erteilt werden , wenn es darauf ankommt. - Die haben damals das Virus direkt am Menschen getestet und gewisse Schritte einfach übersprungen.
5. Natürlich wird es einen Konkurrenzkampf geben. Es ist anzunehmen, dass eine Firma alleine nicht in der Lage sein wird, die Welt mit Impfstoffen zu versorgen.
6. Man könnte auch Roche-Aktien kaufen. Zurzeit ist Tamiflu vielversprechend. Allerdings ist Tamiflu für Roche nur ein Nebengleis. Ist ja ne riesige Firma. Es ist daher nicht anzunehmen, dass eine Vogelgrippe bei Roche einen Vervielfacher auslösen wird.
7. China ist ein riesiger Markt.
8. Auch im obigen Artikel wird darauf hingewiesen, dass noch weitere Tests nötig sind.
9. Die meisten Menschen wissen noch nicht einmal, dass es eine Pandemie geben könnte. Aber die Biotechs wissen das schon lange. Wenn die Vogelgrippe ausbrechen wird, gibt es einen Hype bei Biotechs, welche Impfstoffe gegen die Vogelgrippe entwickeln. Sobald ein Impfstoff da ist, werden vermutlich alle sagen - jetzt kaufen. Gerade dann ist aber der Zeitpunkt um auszusteigen. - War bei SARS auch so. Aktie ist von 0.2 auf 6 Dollar gestiegen. Im März 2004 haben dann alle " kaufen" geschrien. Dann gings aber wieder runter mit dem Kurs.
Buy on bad news, sell on good news. Das ist ja der Witz der Sache. Wenn sich alle der Gefahr einer Pandemie bewusst wären, könnte man Sinovac nicht zum Kurs von 3.5$ kaufen.
@Blanca_die_Haesin
Dein Hinweis ist berechtigt. Ich denke, dass bei einem Hype die " Kleinen" immer am stärksten profitieren. Es wird niemand mit Bestimmtheit sagen können, wer das Rennen macht. Bei SARS ist Sinovac von 0.2 auf 6 Dollar gestiegen. Als dann der wirksame Impfstoff entwickelt wurde, sank die Aktie wieder.
Wie gesagt, ich denke die " Kleinen" werden eher einen Vervielfacher hinlegen. Roche kannst du für den grösseren Teil des Vermögens brauchen. (Wenig Risiko, einfach sein lassen, die steigen auch so - und ne prima Dividende gibts auch) - Aber den Vervielfacher wirst du dort weniger schnell erleben. Sinovac hat zudem noch ne blendende Produktepipeline.
Grüsse
notebook
Dein Hinweis ist berechtigt. Ich denke, dass bei einem Hype die " Kleinen" immer am stärksten profitieren. Es wird niemand mit Bestimmtheit sagen können, wer das Rennen macht. Bei SARS ist Sinovac von 0.2 auf 6 Dollar gestiegen. Als dann der wirksame Impfstoff entwickelt wurde, sank die Aktie wieder.
Wie gesagt, ich denke die " Kleinen" werden eher einen Vervielfacher hinlegen. Roche kannst du für den grösseren Teil des Vermögens brauchen. (Wenig Risiko, einfach sein lassen, die steigen auch so - und ne prima Dividende gibts auch) - Aber den Vervielfacher wirst du dort weniger schnell erleben. Sinovac hat zudem noch ne blendende Produktepipeline.
Grüsse
notebook
" Wir erwarten eine verheerende Influenza-Pandemie innerhalb der kommenden Monate in Deutschland" , verkündete kürzlich Adel Massaad, Leiter des deutschen Instituts für Gesundheitsaufklärung (IFGA).
Quelle: http://tinyurl.com/d4kgh
Quelle: http://tinyurl.com/d4kgh
http://tinyurl.com/73ojh
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Venture Capitalist Situation No. 1: Make 15-90 Times Your Money and Crush SARS, Hepatitis and the Flu
Virtually unknown in the United States, this small company is beloved in China. You see, there`s a colossal epidemic of hepatitis in China, with more than 200 million Chinese estimated to be infected with one strain or another.
Not surprisingly, China is the third highest consumer of hepatitis medicine in the world. However, 90% of that medicine is a dangerous vaccine, sometimes causing liver, spleen and lung damage to the patients receiving it. The other 10% is a much safer variety.
China is about to mandate a change to the safer vaccine. And our small biotech company makes half of the output of it. This policy change alone will instantly increase the company`s hepatitis market 10-fold.
But it gets better. You see, our little prize company is the only Chinese pharmaceutical manufacturer that meets the stringent European GMP (good manufacturing practices) for drugs. That makes it the go-to company when a vaccine absolutely must work.
Millions of Dollars From Ending Flu Vaccine Shortages
Remember our unfortunate lack of conventional flu vaccine during the 2004-2005 flu season? Any major flu outbreak could have been catastrophic.
This company could make that situation a thing of the past.
Its conventional flu vaccine has been approved by the Chinese State Food and Drug Administration, and the company has just built a production facility for this vaccine. That facility can already crank out 2 million doses a year. At $5 a dose, that`s future potential revenue of $10 million right there.
Not bad, considering the company`s market cap is only $100 million!
But this new facility will soon be able to produce up to 20 million doses. During the 2003-2004 flu season in China, 20 million doses were consumed, and about 10-20 million more could have been used had they been available.
Assuming full production, this would equate to $100 million of revenue for this small company. Not only that, but the company is planning a second facility, at a construction cost of a measly $4 million.
Think about it: Where else in the world but China could you build a full-scale vaccine manufacturing plant to world quality standards for a measly $4 million?
But it gets even better...
How to Make Boat Loads of Money When SARS is Destroyed
Most everyone in the world remembers the terrifying outbreak of SARS. We were on pins and needles for a few weeks. We were very lucky on that one. Fortunately, the SARS virus was contained. But there`s no assurance that another strain of SARS won`t break out somewhere else at any time.
Guess who`s the world leader in SARS vaccines? Our little biotech company. In fact, it`s the only company in the world that has received official approval to conduct human clinical trials on a SARS vaccine. It passed Phase 1 with flying colors. Phase 2 has already started.
This tiny company has the full backing (and funding) of the Chinese government to get this vaccine to market as fast as possible. That should happen in the next year or two. In a new epidemic situation, however, the vaccine would be approved on an emergency basis. This would cause an immediate explosion of revenues for the company. This alone could easily make you 10-15 times your money.
And this is still just the beginning of the story...
The Mega-Wealth-Creating Wild Card 90 Times Your Money or More by Declaring War on the World`s Next Black Death Epidemic
Unfortunately, a new virus is developing that will make SARS look like a bad cold. This one could literally threaten the life of everyone on Earth, wiping out 5-10% of the human population.
Sound like a bad science-fiction novel? Believe me, this one`s for real. This super-flu has wiped out 72% of the known cases of human infection. It`s the greatest threat facing the world today, according to a top epidemiologist at the University of Minnesota.
Currently, there is only one drug that stands a chance of blocking this horrible virus. And it`s in very short supply. No way could it stop a worldwide epidemic.
The good news is this minuscule company is already developing a vaccine against this super-flu, in a unique partnership with the Chinese Center for Disease Control and Prevention.
Given the company`s total focus on epidemic prevention, backed by the massive power of the Chinese government, this company could lead the way and will ultimately bring a successful super-flu vaccine to market.
When that happens, our tiny biotech company could own the world commercial rights to that vaccine. Let`s take a few minutes to discuss the potential.
All known cases of this super-flu are currently contained in Southeast Asia. But that may not always be the case. If it somehow gets out of this area, it could spread like wildfire. Klaus Stohr of the World Health Organization`s global influenza program recently declared, " It will go around the globe, and nothing will stop it."
Remember, no human immunity to this virus has been found. In a worldwide epidemic, everyone on the planet would potentially need this vaccine in a widespread epidemic. That`s a potential market of 6 billion people. At a conservative estimate of $5 a dose, that`s $30 billion in revenues to our tiny company.
Of course, it`s not realistic to say that everyone in the world will need the vaccine. After all, we have the ways and means to control an epidemic, containing it to certain areas.
But part of that containment process involves creating buffer zones against the spread of the infection. That would lead to at least 5-10% of the world`s population being chosen for the vaccine. In that scenario, about $1.5 billion in revenues would be generated for our company.
So what does all this mean to potential investors?
If things go as we suspect they will, taking into consideration just the hepatitis vaccine, the conventional flu vaccine and the SARS virus vaccine, conservative estimates for this little medical dynamo show a 1,412% return over the next year, or over 15 times your money.
But the wild card is the super-flu vaccine.
In the conservative scenario discussed above, $1.5 billion in revenues would easily equate to $300 million in net profits for this little company. This would create a situation where you would realistically make 90 Times Your Money - or More!
This is no amateur-hour, pie-in-the-sky company.
Meet the Brilliant Masterminds and Prestigious Financial Advisers Behind This Company
The CEO is a man voted by the American Biographical Institute as one of the world`s 500 most influential leaders. This brilliant professor of biochemistry heads several other highly influential commissions and associations steering the medical industry in China.
The president has been involved in hepatitis research and development for over 20 years, and was the inventor of the safer variation of the hepatitis vaccine. The Chinese government placed him in charge of researching the development of the SARS vaccine.
These well-connected, well-respected men have just executed a brilliant maneuver to further set this company apart from the usual Chinese company. They have employed the services of the world-renowned Credit Suisse, one of the world`s largest and most respected investment banks, to act as the company`s exclusive financial adviser.
For Credit Suisse to even be bothered with this company speaks volumes. After all, in this age of financial scandal such as the Enron and Arthur Andersen collapses, a company as prestigious as Credit Suisse cannot afford to mar its reputation by being associated with a substandard company.
The worst part of this company, by far, has to be its investor relations section. Otherwise, the stock price would be much, much higher.
But even that is about to change.
The company has just hired a prestigious U.S. firm to provide public and investor relations services in North America. And the president of this company did a highly unusual thing.
He personally flew to China to check this company out. He got completely up to speed on the major areas of business and technology operations, agreements and strategies. He toured the company facilities. He went over everything with a fine-toothed comb.
And then he immediately bought 550,000 shares of this company. This is one investor relations executive who puts his money where his mouth is!
Bottom line: With the incredible research and development facilities of this company, with the products already in the commercial pipeline, with the full backing and funding of the Chinese government, with the influential management in place and with world-renowned companies heading its financial advisory and investor relations departments, this tiny biotech company could easily make you...10-90 Times Your Money in the Next Few Years!
Bei SARS ist Sinovac von 0.2 auf 6 Dollar gestiegen!!! - VOR DER ENTWICKLUNG EINES GEGENMITTELS!! -
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 217 | ||
| 90 | ||
| 77 | ||
| 60 | ||
| 50 | ||
| 36 | ||
| 34 | ||
| 31 | ||
| 27 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 19 | ||
| 19 | ||
| 19 | ||
| 19 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 16 | ||
| 15 | ||
| 14 |
